We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Including the recent investment projects announcement, GHIT has invested approximately 14.1 billion yen ($124 million) in 77 global product development partnerships.
The new grant from the GHIT Fund will further development of processes to move the vaccine from the experimental stage to human trials and, ultimately, a clinical treatment.